相关实验视频
Updated: Jul 18, 2026

06:35
Basics of Multivariate Analysis in Neuroimaging Data
Published on: July 24, 2010
16.9K
大脑结构衰老 - - 一个用于多种疾病分类的新生物标志物.
Huy-Dung Nguyen1, Michaël Clément1, Boris Mansencal1
1Univ. Bordeaux, CNRS, Bordeaux INP, LaBRI, UMR 5800, Talence, France.
Human brain mapping
|January 15, 2024
概括
这项研究引入了用MRI扫描对大脑结构年龄的估计,改善了全球大脑年龄预测. 这种新型生物标志物有助于检测人口层面的异常,并在个人层面诊断神经疾病.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 神经学 神经学
背景情况:
- 时间学年龄是大脑解剖学和衰老的一个关键因素.
- 偏离正常的大脑衰老轨迹可能表明神经系统疾病.
- 目前的大脑年龄差距指标不足以进行详细的疾病分类.
研究的目的:
- 用结构性MRI将全球大脑年龄估计扩展到个体大脑结构年龄.
- 开发一种用于异常检测和神经疾病差异诊断的新型生物标志物.
- 增强神经成像在理解大脑衰老和疾病方面的临床实用性.
主要方法:
- 利用一组深度学习模型从结构性MRI生成3D语音智能衰老地图.
- 采用3D细分面具来得出特定的大脑结构年龄.
- 验证了群体级异常检测和主体级疾病分类的方法.
主要成果:
- 估计大脑结构年龄的拟议方法优于现有的异常检测最先进的方法.
- 大脑结构年龄偏差为多种疾病的分类和差异诊断提供了强大的功能.
- 对个体大脑结构年龄偏差的可视化提供了对大脑异常的临床见解.
结论:
- 大脑结构年龄估计为神经疾病分析提供了比全球大脑年龄更具信息性的生物标志物.
- 这种方法增强了在人群层面的异常检测和在主体层面的差异诊断.
- 开发的生物标志物具有显著的潜力,可以通过可视化大脑异常来帮助临床医生在医疗环境中.
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

